|
1
|
Jing N and Tweardy DJ: Targeting Stat3 in
cancer therapy. Anticancer Drugs. 16:601–607. 2005.
|
|
2
|
Blaskovich MA, Sun J, Cantor A, Turkson J,
Jove R and Sebti SM: Discovery of JSI-124 (cucurbitacin I), a
selective Janus kinase/signal transducer and activator of
transcription 3 signaling pathway inhibitor with potent antitumor
activity against human and murine cancer cells in mice. Cancer Res.
63:1270–1279. 2003.
|
|
3
|
Lirdprapamongkol K, Sakurai H, Abdelhamed
S, Yokoyama S, Athikomkulchai S, Viriyaroj A, Awale S, Ruchirawat
S, Svasti J and Saiki I: Chrysin overcomes TRAIL resistance of
cancer cells through Mcl-1 downregulation by inhibiting STAT3
phosphorylation. Int J Oncol. 43:329–337. 2013.
|
|
4
|
Gheeya JS, Chen QR, Benjamin CD, Cheuk AT,
Tsang P, Chung JY, Metaferia BB, Badgett TC, Johansson P, Wei JS,
Hewitt SM and Khan J: Screening a panel of drugs with diverse
mechanisms of action yields potential therapeutic agents against
neuroblastoma. Cancer Biol Ther. 8:2386–2395. 2009.
|
|
5
|
Wang Q, Zhuang X, Mu J, Deng ZB, Jiang H,
Zhang L, Xiang X, Wang B, Yan J, Miller D and Zhang HG: Delivery of
therapeutic agents by nanoparticles made of grapefruit-derived
lipids. Nat Commun. 4:18672013.
|
|
6
|
Molavi O, Ma Z, Hamdy S, Lai R,
Lavasanifar A and Samuel J: Synergistic antitumor effects of CpG
oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse
melanoma tumor model. Immunol Cell Biol. 86:506–514. 2008.
|
|
7
|
Ishdorj G, Johnston JB and Gibson SB:
Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway
independent of apoptosis and cell cycle arrest in B leukemic cells.
BMC Cancer. 11:2682011.
|
|
8
|
McFarland BC, Gray GK, Nozell SE, Hong SW
and Benveniste EN: Activation of the NF-κB pathway by the STAT3
inhibitor JSI-124 in human glioblastoma cells. Mol Cancer Res.
11:494–505. 2013.
|
|
9
|
Lopez-Haber C and Kazanietz MG:
Cucurbitacin I inhibits Rac1 activation in breast cancer cells by a
reactive oxygen species-mediated mechanism and independently of
Janus tyrosine kinase 2 and P-Rex1. Mol Pharmacol. 83:1141–1154.
2013.
|
|
10
|
Hsu HS, Huang PI, Chang YL, Tzao C, Chen
YW, Shih HC, Hung SC, Chen YC, Tseng LM and Chiou SH: Cucurbitacin
I inhibits tumorigenic ability and enhances radiochemosensitivity
in nonsmall cell lung cancer-derived CD133-positive cells. Cancer.
117:2970–2985. 2011.
|
|
11
|
Knecht DA, LaFleur RA, Kahsai AW, Argueta
CE, Beshir AB and Fenteany G: Cucurbitacin I inhibits cell motility
by indirectly interfering with actin dynamics. PLoS One.
11:e140392010.
|
|
12
|
Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z
and Zhang J: JSI-124 inhibits glioblastoma multiforme cell
proliferation through G(2)/M cell cycle arrest and apoptosis
augment. Cancer Biol Ther. 7:1243–1249. 2008.
|
|
13
|
Yang C, Lee H, Pal S, Jove V, Deng J,
Zhang W, Hoon DS, Wakabayashi M, Forman S and Yu H: B cells promote
tumor progression via STAT3 regulated-angiogenesis. PLoS One.
8:e641592013.
|
|
14
|
Kujawski M, Kortylewski M, Lee H, Herrmann
A, Kay H and Yu H: Stat3 mediates myeloid cell-dependent tumor
angiogenesis in mice. J Clin Invest. 118:3367–3377. 2008.
|
|
15
|
Calò V, Migliavacca M, Bazan V, Macaluso
M, Buscemi M, Gebbia N and Russo A: STAT proteins: from normal
control of cellular events to tumorigenesis. J Cell Physiol.
197:157–168. 2003.
|
|
16
|
Ashizawa T, Miyata H, Iizuka A, Komiyama
M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe
R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai
A, Nakasu Y, Yamaguchi K and Akiyama Y: Effect of the STAT3
inhibitor STX-0119 on the proliferation of cancer stem-like cells
derived from recurrent glioblastoma. Int J Oncol. 43:219–227.
2013.
|
|
17
|
Subramaniam A, Shanmugam MK, Perumal E, Li
F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM
and Sethi G: Potential role of signal transducer and activator of
transcription (STAT)3 signaling pathway in inflammation, survival,
proliferation and invasion of hepatocellular carcinoma. Biochim
Biophys Acta. 1835:46–60. 2013.
|
|
18
|
Diaz N, Minton S, Cox C, Bowman T, Gritsko
T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee
JH, Beam CA, Sullivan D, Jove R and Muro-Cacho CA: Activation of
stat3 in primary tumors from high-risk breast cancer patients is
associated with elevated levels of activated SRC and survivin
expression. Clin Cancer Res. 12:20–28. 2006.
|
|
19
|
Gritsko T, Williams A, Turkson J, Kaneko
S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S,
Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S,
Muro-Cacho CA and Jove R: Persistent activation of stat3 signaling
induces survivin gene expression and confers resistance to
apoptosis in human breast cancer cells. Clin Cancer Res. 12:11–19.
2006.
|
|
20
|
Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q,
Zhu J, Wei B and Tang Y: STAT3, a poor survival predicator, is
associated with lymph node metastasis from breast cancer. J Breast
Cancer. 16:40–49. 2013.
|
|
21
|
Ono M, Tanaka N and Orita K: Positive
interactions between human interferon and cepharanthin against
human cancer cells in vitro and in vivo. Cancer Chemother
Pharmacol. 35:10–16. 1994.
|
|
22
|
Lu W, Lin C, Roberts MJ, Waud WR, Piazza
GA and Li Y: Niclosamide suppresses cancer cell growth by inducing
Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin
pathway. PLoS One. 6:e292902011.
|
|
23
|
Nizamutdinova IT, Lee GW, Son KH, Jeon SJ,
Kang SS, Kim YS, Lee JH, Seo HG, Chang KC and Kim HJ: Tanshinone I
effectively induces apoptosis in estrogen receptor-positive (MCF-7)
and estrogen receptor-negative (MDA-MB-231) breast cancer cells.
Int J Oncol. 33:485–491. 2008.
|
|
24
|
Olkhanud PB, Damdinsuren B, Bodogai M,
Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP and Biragyn A:
Tumor-evoked regulatory B cells promote breast cancer metastasis by
converting resting CD4+ T cells to T-regulatory cells.
Cancer Res. 71:3505–3515. 2011.
|
